Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[EGFR mutations in patients with advanced NSCLC].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti - 1 Jan 2012

Fiala O, Pešek M, Fínek J, Brůha F, Bortlíček Z, Krejčí J, Benešová L, Minárik M

Abstract excerpt

BACKGROUND: Molecular targeted therapy based on tyrosine kinase inhibitors, directed at the epidermal growth factor receptor (EGFR) is one of novel options for management of NSCLC. EGFR gene mutations, exon 19 deletions and exon 21 point mutations (L858R) are good predictors of response to EGFR-T...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 22920167

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22920167-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[EGFR mutations in patients with advanced NSCLC].PMID 22920167Read ↗

[EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].Semantic proximity Read ↗

[Detection and evaluation of EGFR mutation status in serum of patients with advanced non-small cell lung cancer treated with EGFR-TKIs].Semantic proximity Read ↗

[Clinical characteristics and outcomes of lung cancer patients with EGFR mutations in exons 19 and 21].Semantic proximity Read ↗

[Exon 19 Deletion and Exon 21 L858R Point Mutation in EGFR Mutation‒Positive Non‒Small Cell Lung Cancer].Semantic proximity Read ↗

The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.Semantic proximity Read ↗

[Differences between EGFR Exon 19 Deletion and Exon 21 L858R Point Mutation, Frequently Detected EGFR Mutations in Patients with Non-Small Cell Lung Cancer, from a Molecular Biology Viewpoint].Semantic proximity Read ↗

[EGFR gene mutation status among lung cancer patients in China].Semantic proximity Read ↗

Frequency of EGFR mutations in non-small cell lung cancer patients: screening data from West Siberia.Semantic proximity Read ↗

Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.Semantic proximity Read ↗

The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients.Semantic proximity Read ↗

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.Semantic proximity Read ↗

[Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.